FY2025 · ended Dec 31, 2025 · Revenue $65.18B, +44.7% YoY · Filed Feb 12, 2026
Eli Lilly And Company (LLY) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $65.2 billion and net income of $20.6 billion. As of Sep 30, 2026 it held $8.9 billion in cash and investments and $47.0 billion in total debt.
Revenue (TTM)
$86.46B
+45.5% vs year-ago TTM
Net income (TTM)
$27.58B
+49.8% vs year-ago TTM
Operating cash flow (TTM)
$30.64B
+90.8% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$30.80
+50.7% vs year-ago TTM
Dividend per share (TTM)
$6.69
+15.3% vs year-ago TTM
Shares outstanding
943.36M
-0.5% vs prior year
Net cash
$-38.09B
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LLY (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- IN
- Headquarters
- Indianapolis, IN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 59478
- Former names
- LILLY ELI & CO (until Oct 25, 2019); LILLY ELI & CO ET AL (until Oct 14, 1994)
Other Pharmaceutical Preparations companies
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $65.2B | $45.0B | $34.1B | $28.5B | $28.3B |
| Net income | $20.6B | $10.6B | $5.2B | $6.2B | $5.6B |
| Diluted EPS | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
| Operating cash flow | $16.8B | $8.8B | $4.2B | $7.6B | $7.4B |
| Total assets | $112.5B | $78.7B | $64.0B | $49.5B | $48.8B |
| Stockholders' equity | $26.5B | $14.3B | $10.8B | $10.6B | $9.0B |
| Cash and investments | $10.1B | $6.6B | $6.0B | $5.1B | $7.1B |
| Total debt | $43.9B | $39.1B | $32.5B | $18.5B | $17.6B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Other events
|
May 20, 2026 | May 20, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 7, 2026 | May 4, 2026 |
All 1001 Eli Lilly And Company SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.